808756-71-0

Basic information

• Product Name: N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea
• Synonyms: N-(5-tert-Butylindan-1-yl)-N'-(1H-indazol-4-yl)urea;N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea;ABT-102;1-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-3-(1H-indazol-4-yl)urea
• CAS NO: 808756-71-0
• Molecular Formula: C₂₁H₂₄N₄O
• Molecular Weight: 348.44146
• Mol File: 808756-71-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 529.5 °C at 760 mmHg
• Flash Point: 274.1 °C
• Appearance: /
• Density: 1.24
• Vapor Pressure: 2.68E-11mmHg at 25°C
• Refractive Index: 1.656
• CAS DataBase Reference: N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea(808756-71-0)
• EPA Substance Registry System: N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea(808756-71-0)

Safety Data

• Hazardous Substances Data: 808756-71-0(Hazardous Substances Data)

Usage

General Description

The chemical N-[(1R)-5-(1,1-Dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea is a synthetic compound also known as BI8622. It is a potent and selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A), which plays a role in regulating intracellular levels of the signaling molecule cyclic adenosine monophosphate (cAMP). PDE10A inhibitors like BI8622 have been investigated for their potential therapeutic applications in neuropsychiatric disorders, particularly in the treatment of schizophrenia and Huntington's disease. The compound has shown promise in preclinical studies and is being evaluated in clinical trials for its efficacy and safety.

InChI:InChI=1/C21H24N4O/c1-21(2,3)14-8-9-15-13(11-14)7-10-18(15)24-20(26)23-17-5-4-6-19-16(17)12-22-25-19/h4-6,8-9,11-12,18H,7,10H2,1-3H3,(H,22,25)(H2,23,24,26)/t18-/m1/s1

Upstream product

• 935680-90-3 5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine 
• 4600-86-6 5-(tert-butyl)-2,3-dihydro-1H-inden-1-one 
• 735330-50-4 4-(2,5-dioxopyrrolidin-1-yl-oxycarbonylamino)indazole-1-carboxylic acid methyl ester 
• 934593-36-9 (1R)-5-tert-butyl-indan-1-ylamine tosylate 
• 28547-33-3 1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one 
• 253185-03-4 tert-butylbenzene 
• 808756-69-6 methyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate 
• 952734-48-4 (R)-1-(2-benzyl-2H-indazol-4-yl)-3-(5-tert-butyl-2,3-dihydro-1H-indan-1-yl)urea 

Relevant articles and documents

Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H- indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management

Vanilloid receptor TRPV1 is a cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical companies in an effort to identify novel agents for pain management. Here we report that replacement of substituted benzyl groups by an indan rigid moiety in a previously described N-indazole-N′-benzyl urea series led to a number of TRPV1 antagonists with significantly increased in vitro potency and enhanced drug-like properties. Extensive evaluation of pharmacological, pharmacokinetic, and toxicological properties of synthesized analogs resulted in identification of (R)-7 (ABT-102). Both the analgesic activity and drug-like properties of (R)-7 support its advancement into clinical pain trials.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.